Nirav N. Shah

机构：Medical College of Wisconsin, Johnson & Johnson (India) · ORCID：0000-0002-4336-1071

发表论文 531 篇 · 总被引 9744 次 · h-index 46

代表论文

• Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study (2025 · Blood · 被引 6)
• Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial (2025 · Blood · 被引 6)
• Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium (2025 · Blood Advances · 被引 2)
• Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study (2025 · Blood · 被引 1)
• Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study (2025 · Blood · 被引 1)
• Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi‐Country Needs Assessment (2026 · Cancer Reports)